JP5816086B2 - 刺激細胞標準 - Google Patents
刺激細胞標準 Download PDFInfo
- Publication number
- JP5816086B2 JP5816086B2 JP2011517241A JP2011517241A JP5816086B2 JP 5816086 B2 JP5816086 B2 JP 5816086B2 JP 2011517241 A JP2011517241 A JP 2011517241A JP 2011517241 A JP2011517241 A JP 2011517241A JP 5816086 B2 JP5816086 B2 JP 5816086B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- fixative
- fixed
- reference material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000004027 cell Anatomy 0.000 claims description 217
- 238000000034 method Methods 0.000 claims description 48
- 108090000695 Cytokines Proteins 0.000 claims description 42
- 102000004127 Cytokines Human genes 0.000 claims description 40
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 34
- 239000012925 reference material Substances 0.000 claims description 27
- 239000000834 fixative Substances 0.000 claims description 24
- 238000004108 freeze drying Methods 0.000 claims description 23
- 238000003860 storage Methods 0.000 claims description 21
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 claims description 15
- 239000003226 mitogen Substances 0.000 claims description 15
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 230000000638 stimulation Effects 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 10
- 229930040373 Paraformaldehyde Natural products 0.000 claims description 9
- 229920002866 paraformaldehyde Polymers 0.000 claims description 9
- 241001465754 Metazoa Species 0.000 claims description 8
- 239000003112 inhibitor Substances 0.000 claims description 8
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 claims description 8
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 claims description 8
- 239000002577 cryoprotective agent Substances 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 230000004936 stimulating effect Effects 0.000 claims description 7
- 229910021555 Chromium Chloride Inorganic materials 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 claims description 6
- 230000028327 secretion Effects 0.000 claims description 6
- KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 claims description 4
- JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 claims description 4
- 230000001419 dependent effect Effects 0.000 claims 4
- 239000002953 phosphate buffered saline Substances 0.000 description 15
- 230000008901 benefit Effects 0.000 description 11
- 210000004698 lymphocyte Anatomy 0.000 description 11
- 238000000684 flow cytometry Methods 0.000 description 10
- 210000004962 mammalian cell Anatomy 0.000 description 10
- 238000003556 assay Methods 0.000 description 9
- 210000001772 blood platelet Anatomy 0.000 description 9
- 230000003834 intracellular effect Effects 0.000 description 8
- 238000011510 Elispot assay Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- -1 succinimidyl ester Chemical class 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 238000012792 lyophilization process Methods 0.000 description 5
- 210000001616 monocyte Anatomy 0.000 description 5
- 210000000822 natural killer cell Anatomy 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 210000000440 neutrophil Anatomy 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 206010061598 Immunodeficiency Diseases 0.000 description 4
- 208000029462 Immunodeficiency disease Diseases 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 238000001516 cell proliferation assay Methods 0.000 description 4
- 230000016396 cytokine production Effects 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000007813 immunodeficiency Effects 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- 210000003651 basophil Anatomy 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 210000003979 eosinophil Anatomy 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000003278 mimic effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 108010047620 Phytohemagglutinins Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 208000030452 Transient pseudohypoaldosteronism Diseases 0.000 description 2
- 241000589886 Treponema Species 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 230000036436 anti-hiv Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000035931 haemagglutination Effects 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 229960001438 immunostimulant agent Drugs 0.000 description 2
- 239000003022 immunostimulating agent Substances 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000001885 phytohemagglutinin Effects 0.000 description 2
- 238000005057 refrigeration Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 208000006379 syphilis Diseases 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- QGVLYPPODPLXMB-UBTYZVCOSA-N (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-4a,7b,9,9a-tetrahydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-1,1a,1b,4,4a,7a,7b,8,9,9a-decahydro-5H-cyclopropa[3,4]benzo[1,2-e]azulen-5-one Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(O)C(C)(C)[C@H]3[C@@H]21 QGVLYPPODPLXMB-UBTYZVCOSA-N 0.000 description 1
- SRSXVRUMXPCNAJ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3',6'-diacetyloxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-5-carboxylate Chemical compound C=1C(OC(=O)C)=CC=C2C=1OC1=CC(OC(C)=O)=CC=C1C2(C1=CC=2)OC(=O)C1=CC=2C(=O)ON1C(=O)CCC1=O SRSXVRUMXPCNAJ-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- MURGITYSBWUQTI-UHFFFAOYSA-N Fluorescin Natural products OC(=O)C1=CC=CC=C1C1C2=CC=C(O)C=C2OC2=CC(O)=CC=C21 MURGITYSBWUQTI-UHFFFAOYSA-N 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 229930191564 Monensin Natural products 0.000 description 1
- GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229950004398 broxuridine Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 238000002737 cell proliferation kit Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 238000003271 compound fluorescence assay Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000002790 cross-validation Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 238000005297 material degradation process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 229960005358 monensin Drugs 0.000 description 1
- GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical compound C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- QGVLYPPODPLXMB-QXYKVGAMSA-N phorbol Natural products C[C@@H]1[C@@H](O)[C@]2(O)[C@H]([C@H]3C=C(CO)C[C@@]4(O)[C@H](C=C(C)C4=O)[C@@]13O)C2(C)C QGVLYPPODPLXMB-QXYKVGAMSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0812757A GB0812757D0 (en) | 2008-07-11 | 2008-07-11 | Cell profliferation standards |
| GB0812755A GB0812755D0 (en) | 2008-07-11 | 2008-07-11 | Stimulated cell standards |
| GB0812757.3 | 2008-07-11 | ||
| GB0812755.7 | 2008-07-11 | ||
| PCT/GB2009/050815 WO2010004336A2 (en) | 2008-07-11 | 2009-07-09 | Stimulated cell standards |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011527192A JP2011527192A (ja) | 2011-10-27 |
| JP2011527192A5 JP2011527192A5 (https=) | 2012-07-05 |
| JP5816086B2 true JP5816086B2 (ja) | 2015-11-17 |
Family
ID=41120025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011517241A Expired - Fee Related JP5816086B2 (ja) | 2008-07-11 | 2009-07-09 | 刺激細胞標準 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9267956B2 (https=) |
| EP (1) | EP2316036B1 (https=) |
| JP (1) | JP5816086B2 (https=) |
| CN (1) | CN102144165B (https=) |
| AU (1) | AU2009269765B2 (https=) |
| BR (1) | BRPI0915903A8 (https=) |
| CA (1) | CA2730191C (https=) |
| ES (1) | ES2454320T3 (https=) |
| PT (1) | PT2316036E (https=) |
| WO (1) | WO2010004336A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2834619A1 (en) * | 2012-04-05 | 2015-02-11 | Renishaw Diagnostics Limited | A method for calibrating spectroscopy apparatus and equipment for use in the method |
| CN107576790A (zh) * | 2017-11-03 | 2018-01-12 | 深圳市巴德生物科技有限公司 | 一种冻干人淋巴细胞cd4表面抗原质控品及其制备方法 |
| CN107576788A (zh) * | 2017-11-03 | 2018-01-12 | 深圳市巴德生物科技有限公司 | 一种检测白细胞分化抗原的参照品及其制备方法 |
| CN109925323A (zh) * | 2019-03-29 | 2019-06-25 | 广东先康达生物科技有限公司 | 有效改善骨髓造血微环境的免疫细胞制剂 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE76319B1 (en) * | 1990-07-23 | 1997-10-22 | Becton Dickinson Co | Preservation of cells as controls or standards in cellular analysis |
| AU700699B2 (en) * | 1993-07-05 | 1999-01-14 | Sheffield Teaching Hospitals National Health Service Trust, The | Preparation and stabilisation of cells |
| EP1428008B1 (en) * | 2001-09-06 | 2012-01-18 | Core Dynamics Limited | Improved method for freezing viable cells |
| US7354773B2 (en) * | 2003-05-14 | 2008-04-08 | Beckman Coulter, Inc. | Method and apparatus for preparing cell samples for intracellular antigen detection using flow cytometry |
| WO2006090096A1 (en) * | 2005-02-28 | 2006-08-31 | Sheffield Teaching Hospitals Nhs Foundation Trust | Composition, kit and method for fixing cells |
| JP2009526991A (ja) * | 2006-02-17 | 2009-07-23 | パオロ・ラ・コッラ | 増殖性疾患及び／又はコンホメーション病の診断方法 |
-
2009
- 2009-07-09 EP EP09785294.1A patent/EP2316036B1/en not_active Not-in-force
- 2009-07-09 CN CN200980134557.1A patent/CN102144165B/zh not_active Expired - Fee Related
- 2009-07-09 AU AU2009269765A patent/AU2009269765B2/en not_active Ceased
- 2009-07-09 CA CA2730191A patent/CA2730191C/en not_active Expired - Fee Related
- 2009-07-09 JP JP2011517241A patent/JP5816086B2/ja not_active Expired - Fee Related
- 2009-07-09 PT PT97852941T patent/PT2316036E/pt unknown
- 2009-07-09 US US13/003,661 patent/US9267956B2/en not_active Expired - Fee Related
- 2009-07-09 ES ES09785294.1T patent/ES2454320T3/es active Active
- 2009-07-09 WO PCT/GB2009/050815 patent/WO2010004336A2/en not_active Ceased
- 2009-07-09 BR BRPI0915903A patent/BRPI0915903A8/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010004336A2 (en) | 2010-01-14 |
| CA2730191C (en) | 2018-06-19 |
| BRPI0915903A8 (pt) | 2018-06-12 |
| CN102144165A (zh) | 2011-08-03 |
| EP2316036A2 (en) | 2011-05-04 |
| BRPI0915903A2 (pt) | 2015-10-27 |
| WO2010004336A3 (en) | 2010-04-29 |
| CA2730191A1 (en) | 2010-01-14 |
| ES2454320T3 (es) | 2014-04-10 |
| AU2009269765B2 (en) | 2016-03-03 |
| AU2009269765A1 (en) | 2010-01-14 |
| US9267956B2 (en) | 2016-02-23 |
| CN102144165B (zh) | 2016-11-23 |
| EP2316036B1 (en) | 2013-12-25 |
| JP2011527192A (ja) | 2011-10-27 |
| US20110183372A1 (en) | 2011-07-28 |
| PT2316036E (pt) | 2014-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Richter et al. | Human T cell priming assay (hTCPA) for the identification of contact allergens based on naive T cells and DC–IFN-γ and TNF-α readout | |
| Claus et al. | Comprehensive analysis of NK cell function in whole blood samples | |
| Borchers et al. | Multimer monitoring of CMV-specific T cells in research and in clinical applications | |
| JP5816086B2 (ja) | 刺激細胞標準 | |
| Kotov et al. | Peptide: MHCII Tetramer‐Based Cell Enrichment for the Study of Epitope‐Specific CD4+ T Cells | |
| Juhl et al. | Cryopreservation of peripheral blood mononuclear cells for use in proliferation assays: First step towards potency assays | |
| Fung et al. | Transduction of human T cell subsets with lentivirus | |
| Assenmacher et al. | Detection and isolation of cytokine secreting cells using the cytometric cytokine secretion assay | |
| Helm et al. | Isolation of primary human B lymphocytes from tonsils compared to blood as alternative source for ex vivo application | |
| Hill et al. | Inhibition of activation induced CD154 on CD4+ CD25− cells: a valid surrogate for human Treg suppressor function | |
| Kamali et al. | Sensing acute cellular rejection in liver transplant patients using liver-derived extracellular particles: a prospective, observational study | |
| Hilkens et al. | In vitro generation of human tolerogenic monocyte-derived dendritic cells | |
| Cohen et al. | Can cord blood cells support the cytokine storm in GvHD? | |
| Brooks‐Worrell et al. | Comparison of cryopreservation methods on T‐cell responses to islet and control antigens from type 1 diabetic patients and controls | |
| Atif et al. | Phenotypic and functional studies of human Treg cell subpopulations | |
| Pisania et al. | Enumeration of islets by nuclei counting and light microscopic analysis | |
| Popescu et al. | Phenotypic and functional characterization of cytotoxic T lymphocytes by flow cytometry | |
| HK1160679B (en) | Stimulated cell standards | |
| Xie et al. | In vitro and In vivo CD8+ T Cell Suppression Assays | |
| HK1160679A (en) | Stimulated cell standards | |
| Lv et al. | Luminex-coupled EliFACS: a multiparametric method to enumerate and functionally characterize antigen-specific T cells in human peripheral blood | |
| Newton et al. | Immunophenotyping: Analysis of Nanoparticle Effects on the Composition and Activation Status of Human Peripheral Blood Mononuclear Cells | |
| Markovic et al. | A reproducible method for the enumeration of functional (cytokine producing) versus non-functional peptide-specific cytotoxic T lymphocytes in human peripheral blood | |
| US20250258162A1 (en) | Regulatory t cell stability assay | |
| RU2775967C2 (ru) | Способы и композиции для определения активности терапевтической клеточной композиции |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120521 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120521 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131224 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140324 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140331 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140422 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140430 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140523 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140530 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140624 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150106 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150331 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150501 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150605 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150706 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150901 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150925 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5816086 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |